ArticleOTA international : the open access journal of orthopaedic trauma2021
Bioactive glass in the treatment of chronic osteomyelitis-a valid option?
Article in OTA international : the open access journal of orthopaedic trauma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07227493 (Acute Bone Grafting of Open Pilon Fractures With FIBERGRAFT AERIDYAN Matrix Bioactive Glass), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acute Bone Grafting of Open Pilon Fractures With FIBERGRAFT AERIDYAN Matrix Bioactive Glass
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- A systematic review on bioactive glass as a treatment for limb osteomyelitis and infected nonunion.Bone & joint open · 2025Pooled it
- Current and emerging biomaterials for targeted drug delivery in osteomyelitis management.Discover nano · 2026Review
- How Bioactive Glass S53P4 Kills Bacteria.Journal of functional biomaterials · 2026Article
- Bioactive glass S53P4 cream kills ESKAPE panel multidrug resistant pathogens andFrontiers in pharmacology · 2026Article
- Article
- Surgical treatment of unstable spondylodiscitis with posterior instrumentation and bioactive glass (BAG-S53P4): surgical technique and results at medium-term follow-up.Journal of spine surgery (Hong Kong) · 2025Article
- Biological aspects to enhance fracture healing.EFORT open reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic osteomyelitis continues to represent a challenge both for patients and the treating physician, especially in the presence of multiple germs. We performed a literature review assessing the current role of the indications of bioactive glass. We included studies about patients with chronic osteomyelitis that were treated with S53P4. A literature review of Medline via PubMed was performed. After the exclusion of case reports, 7 studies were included in the narrative review. Recurrence of infection was defined as the main outcome parameter. Six of 7 studies were retrospective, or case studies with a relatively small sample size (total patient number N = 274). The overall recurrence rate was 10.6%. Studies that compared the outcome of the treatment with S53P4 versus antibiotic-loaded polymethyl methacrylate (PMMA) revealed no significant difference. The data reviewed indicate that in cases of multiple bacteria and resistance to antibiotic treatment, bioglass may be a valuable treatment alternative to other forms of spacers (e.g., PMMA). This statement is limited by the fact that the number of described cases is very low. Therefore, a definitive statement of its effectiveness cannot be made at this point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.